Peer-Reviewed Study Confirms Reliability of ColoSense, Geneoscopy’s Noninvasive Multi-target Stool RNA Colorectal Cancer Screening Test (Geneoscopy)

Geneoscopy’s ColoSense™, a noninvasive multi-target stool RNA (mt-sRNA) test, has been validated in a peer-reviewed study published in The Journal of Molecular Diagnostics. This FDA-approved test demonstrated high stability, precision, and reproducibility, achieving 93% sensitivity for colorectal cancer (CRC) and 45% for advanced adenomas (AAs) in average-risk individuals aged 45 and older. The study’s findings highlight ColoSense as a reliable alternative to traditional invasive methods, potentially transforming CRC screening practices. Could this innovation mark a new era in noninvasive cancer diagnostics?